SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
December 13 2023 - 8:30AM
SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device
company developing proprietary solutions to reduce the consequences
of dysregulated immune responses including hyperinflammation on
vital organs, announces the formation of the SeaStar Medical
Scientific Advisory Board (SAB).
The SAB is comprised of world-renowned
international pediatric and adult clinical experts including
nephrologists, critical care intensivists and translational
scientists who will advise on the Company’s technology
capabilities, share insights on emerging trends in healthcare, and
advise on the Company’s critical care and acute kidney injury (AKI)
clinical development programs.
“Science and innovation are the foundational
pillars of SeaStar Medical and key to our competitive advantage,”
said Eric Schlorff, CEO of SeaStar Medical. “We are grateful to be
collaborating with this incredible group of top clinical experts
and scientists as we continue to develop and commercialize our
selective cytopheretic device (SCD). We plan to further broaden our
SAB with relevant expertise as we expand beyond our initial AKI
clinical programs into other therapeutic categories and
indications.”
Members of SeaStar Medical’s SAB include the
following:
- Ayse
Akcan-Arikan, MD is the Medical Director of Critical Care
Nephrology and Acute Dialysis at Texas Children’s Hospital and
Associate Professor of Pediatrics, Baylor College of Medicine
- David
Askenazi, MD, MSPH is the Director of Pediatric and Infant
Center for Acute Nephrology (PICAN) at Children’s of Alabama and
Professor at the University of Alabama at Birmingham
- Sean
Bagshaw, MD, MSc is the Chair of Critical Care Medicine
and Associate Professor of Critical Care Medicine at the University
of Alberta
- Rajit
Basu, MD, MS is the Division Head of Critical Care
Medicine at the Lurie Children’s Hospital of Chicago and Professor
of Pediatrics at Northwestern University Feinberg School of
Medicine
- Andriy
Batchinsky, MD is the Founder and Director of the
Autonomous Reanimation and Evacuation (AREVA) Program at the Geneva
Foundation
- Sarah
Faubel, MD is Professor of Medicine and Nephrologist at
the University of Colorado Hospital and Veterans Affairs Medical
Center
- Stuart
Goldstein, MD is the Director of the Center for Acute Care
Nephrology and Medical Director of Pheresis Service, Co-Director of
the Heart Institute Research Core at Cincinnati Children’s Medical
Hospital and Professor at the University of Cincinnati’s Department
of Pediatrics
- Marc
Jeschke, MD, PhD is the Vice President and Medical
Director of Burns and Translational Researcher at Hamilton Health
Sciences
- Jay
Koyner, MD is the Medical Director of Acute Dialysis and
Director of Nephrology Intensive Care Unit at the University of
Chicago Medical Center
- Kathleen
Liu, MD, PhD is a critical care intensivist, and Professor
of Medicine and clinical trialist at the University of California
at San Francisco School of Medicine
- Theresa
Mottes, MSN, APRN-NP, CPNP-AC, CDN is an Acute Care Nurse
Practitioner at the Lurie Children’s Hospital of Chicago
“Several of our SAB members provided key support
during discussions with the U.S. Food and Drug Administration
(FDA), which resulted in the Approvable Letter for the SCD’s
humanitarian device exemption (HDE) in pediatric AKI,” said Kevin
Chung, MD, Chief Medical Officer of SeaStar Medical. “The advisory
board also advised on design elements of our ongoing, pivotal
NEUTRALIZE-AKI Phase 3 study with the SCD in adult patients with
AKI. We look forward to continued engagement and collaborations
with these invaluable experts.”
About SeaStar MedicalSeaStar
Medical is a medical technology company that is redefining how
extracorporeal therapies may reduce the consequences of excessive
inflammation on vital organs. SeaStar Medical’s novel technologies
rely on science and innovation to provide life-saving solutions to
critically ill patients. The Company is developing and
commercializing cell-directed extracorporeal therapies that target
the effector cells that drive systemic inflammation, causing direct
tissue damage and secreting a range of pro-inflammatory cytokines
that initiate and propagate imbalanced immune responses. For more
information visit www.seastarmedical.com or visit us on LinkedIn or
Twitter.
Forward-Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1955. These forward-looking
statements include, without limitation, SeaStar Medical’s
expectations with respect to commercialization of SeaStar’s product
candidates and contribution from industry experts. Words such as
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions are intended to identify such
forward-looking statements. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to significant risks and uncertainties that
could cause the actual results to differ materially from the
expected results. Most of these factors are outside SeaStar
Medical’s control and are difficult to predict. Factors that may
cause actual future events to differ materially from the expected
results include, but are not limited to: (i) the risk that SeaStar
Medical may not be able to obtain regulatory approval of its SCD
product candidates; (ii) the risk that SeaStar Medical may not be
able to raise sufficient capital to fund its operations, including
clinical trials; (iii) the risk that SeaStar Medical and its
current and future collaborators are unable to successfully develop
and commercialize its products or services, or experience
significant delays in doing so, including failure to achieve
approval of its products by applicable federal and state
regulators, (iv) the risk that SeaStar Medical may never achieve or
sustain profitability; (v) the risk that SeaStar Medical may not be
able to access funding under existing agreements, including the
equity line of credit and forward purchase agreements; (vi) the
risk that third-parties suppliers and manufacturers are not able to
fully and timely meet their obligations, (vii) the risk of product
liability or regulatory lawsuits or proceedings relating to SeaStar
Medical’s products and services, (viii) the risk that SeaStar
Medical is unable to secure or protect its intellectual property,
and (ix) other risks and uncertainties indicated from time to time
in SeaStar Medical’s Annual Report on Form 10-K, including those
under the “Risk Factors” section therein and in SeaStar Medical’s
other filings with the SEC. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and SeaStar Medical assume no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:
LHA Investor RelationsJody Cain(310)
691-7100Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Apr 2024 to May 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From May 2023 to May 2024